Accuray ( NASDAQ: ARAY ) has announced that the registration dossier for the Accuray Precision ® Treatment Planning System has been approved by the Chinese National Medical Products Administration. The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo ® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China. The Accuray Precision TPS was developed to facilitate the creation and adaptation of precise treatment plans in less time.
With this approval our China joint venture can begin shipping the Tomo C System to their end customers, an important step forward in helping to address an unmet need for precision radiation therapy," said Suzanne Winter, president and CEO. More on Accuray Accuray Incorporated (ARAY) Q3 2024 Earnings Call Transcript Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp Accuray GAAP EPS of -$0.06 misses by $0.
05, revenue of $101.1M misses by $12.55M Accuray Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on Accuray.
